Abstract
Antifibrotic effect of the ethyl acetate fraction of ciplukan (Physalis angulata Linn.) in rat liver fibrosis induced by CCI4
Highlights
Liver fibrosis is the leading cause of mortality worldwide.In 2016, the Centers for Disease Control and Prevention stated that there were 4.9 million persons in the United States who had liver disease
Ciplukan (Physalis angulata Linn.) is a Solanaceae family species and contains various active compounds with diverse therapeutic potential. The goal of this investigation was to see if the ethyl acetate fraction of ciplukan had an antifibrotic impact on liver fibrosis
In rat liver fibrosis induced by CCl4, these findings suggest that the ethyl acetate fraction of ciplukan has an antifibrotic effect
Summary
Liver fibrosis is the leading cause of mortality worldwide. In 2016, the Centers for Disease Control and Prevention stated that there were 4.9 million persons in the United States who had liver disease. Liver diseases are the sixth leading cause of death at 25– 64 years of age (Shipley et al, 2019). Liver fibrosis is a pathological condition that develops when the liver’s stiff fibrotic connective tissue proliferates and accumulates abnormally. The fibrotic connective tissue that creates scar tissue is a typical response to injury, but chronic stimulation of inflammatory cells promotes abnormal tissue repair in the fibrosis formation process. Hepatic stellate cells (HSCs) are activated and produce collagen, glycoproteins
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.